Improving survival following surgery for pancreatic ductal adenocarcinoma--a ten-year experience

Riferimento: 
Eur J Surg Oncol. 2012 Mar;38(3):245-51.
Autori: 
Hoem D, Viste A.
Fonte: 
Eur J Surg Oncol. 2012 Mar;38(3):245-51.
Anno: 
2012
Azione: 
A pazienti con adenocarcinomi duttali possono essere offerte eventuali resezioni curative mentre l'uso profilattico dell'octreotide deve essere limitato ogni volta che l'anastomosi è considerata a rischio.
Target: 
Octreotide/adenocarcinomi duttali.

ABSTRACT
OBJECTIVE:
Report results following pancreatic surgery at a tertiary referral hospital in Norway, and our experience with the effects of preoperative use of common bile duct stents, the prophylactic efficacy of octreotide, and explore significant survival factors.
MATERIAL AND METHODS:
Prospective observational study of 275 patients during the years 1999-2009.
RESULTS:
Ninety-two ductal adenocarcinomas were operated, and 183 cases were inoperable. Pylorus preserving pancreatico-duodenectomy (PPPD) was performed in 42 cases, a classic Whipple procedure (WP) in 38, distal resection in 6 and total pancreatectomy in 6 patients. Median size of the tumours was 3 cm R(0) resection was obtained in 54 patients. Lymph node metastases were found in 64 patients. 20% experienced postoperative intra-abdominal complications, and 30 days postoperative mortality was 4%. A routine use of somatostatine analogues postoperatively did not reduce the frequency of leakage. Two years survival was 34.6% and 5 years 11.8%, respectively.
CONCLUSIONS:
Patients with ductal adenocarcinomas can be offered potential curative resections with acceptable rates of complication and mortality. Preoperative biliary stenting is still controversial and prophylactic octreotide should be used whenever the anastomosis is considered challenged and in cases of a soft pancreatic remnant. Five years all over survival has improved over the last decade from <5% to >11%.